亿帆医药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第八届 董事会第十六次会议及第八届监事会第十三次会议，均审议通过了《关于公司 2024 年度利润分配预案的议案》，本议案尚需提交公司 2024 年年度股东会审议， 现将有关情况公告如下： 二、本次利润分配预案的基本情况 1、公司 2024 年度可分配利润情况 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 021 亿帆医药股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 2024 年半年度，公司进行了现金分红，以公司现有总股本 1,226,024,827 股 扣除回购专户上已回购股份 9,634,742 股后的总股本 1,216,390,085 股为基数，向 全体股东每 10 股派现金 1 元（含税），共计派发现金 121,639,008.50 元，不送 红股，不以资本公积金转增股本。即 2024 年度，公司累计现金分红总额为 243,278,017.00 元。 经立信会计师事务所（特殊普通合伙） ...

Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total of 1,216,390,085 shares[4]. - The board has approved a profit distribution plan that does not include stock dividends or capital reserves conversion[4]. - The total cash dividend amount, including other methods, is 402,265,883.37 yuan, which accounts for 100% of the total profit distribution[198]. - The cash dividend policy was strictly adhered to, with clear standards and procedures in place to protect shareholder interests[197]. - The cash dividend distribution plan is subject to approval at the company's 2024 annual general meeting[200]. - The company has implemented a cash dividend distribution for the first half of 2024, with the same terms as the annual plan[200]. - The total number of shares after deducting repurchased shares is 1,216,390,085 shares for the dividend calculation[200]. Financial Performance - The company's operating revenue for 2024 reached ¥5,159,823,227.64, representing a 26.84% increase compared to ¥4,068,107,333.94 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥385,967,572.95, a significant turnaround from a loss of ¥551,073,063.61 in 2023, marking a 170.04% increase[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,094,095.26, up 146.58% from a loss of ¥532,628,603.81 in the previous year[19]. - Basic earnings per share for 2024 were ¥0.32, compared to a loss of ¥0.45 in 2023, reflecting a 171.11% increase[18]. - The net cash flow from operating activities increased by 83.81% to ¥640,730,192.65, up from ¥348,584,791.89 in 2023[19]. - Total assets at the end of 2024 were ¥12,285,788,088.75, a 6.84% increase from ¥11,499,585,782.14 at the end of 2023[18]. - The net assets attributable to shareholders increased by 2.98% to ¥8,521,867,867.56 at the end of 2024, compared to ¥8,275,633,622.03 at the end of 2023[18]. Revenue Growth and Sources - The company attributed revenue growth to the approval and sales increase of self-developed and imported pharmaceutical products[18]. - The company received government subsidies related to revenue, contributing to the increase in net profit[19]. - Total revenue for the year was approximately CNY 5.16 billion, with a quarterly breakdown showing Q1 at CNY 1.33 billion, Q2 at CNY 1.31 billion, Q3 at CNY 1.23 billion, and Q4 at CNY 1.30 billion[23]. - The company reported a total of CNY 122.15 million in government subsidies for the year, a substantial increase from CNY 41.81 million in the previous year[25]. Market Position and Product Development - Vitamin B5 remains a key product for the company, maintaining a leading position in its niche market despite competitive pressures[34]. - The company is focusing on enhancing operational efficiency and supply chain management to maintain competitive advantages in the vitamin market[34]. - The company has established a high-standard production system for macromolecular drugs that meets the quality requirements of various countries, having passed GMP certifications from NMPA, FDA, and EMA[38]. - The company has successfully commercialized its innovative biological drug, Yilishu, in 34 countries including China, the United States, and the EU[38]. - The company is focusing on developing new products tailored for children's physiological characteristics to enhance the safety and effectiveness of pediatric medications[42]. - The company is positioned as a leader in the vitamin market, with a significant presence in animal nutrition and food additives, driven by a recovery in consumer demand[35]. Research and Development - The company will continue to increase R&D investment to discover, develop, and commercialize drugs that meet unmet clinical needs, in line with the national strategy for innovative drug development[44]. - The company aims to optimize its product portfolio and implement comprehensive measures to adapt to the challenges posed by the reform of medical insurance payment methods, ensuring sustainable development[44]. - The company plans to improve clinical trial design and data analysis to enhance the efficiency of new drug development and accelerate market access[48]. - The company is actively enhancing its international business team to expand its product portfolio through licensing transactions[38]. - The company is focused on increasing its core competitiveness through innovative drug development and international expansion strategies[98]. Risk Management - The company has outlined various risks in its operations, including international trade risks and R&D performance risks[4]. - The company reported uncertainty regarding its ability to continue as a going concern in recent audits[20]. - The company faces risks in drug development due to long cycles and high investment, with potential clinical trial failures impacting profitability[148]. - The company is implementing measures to mitigate foreign exchange risks, including optimizing foreign currency allocation and using financial instruments to lock in exchange rates[151]. - The company is closely monitoring international political and economic environments to manage risks associated with its international operations[152]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, enhancing its internal control systems[158]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with governance requirements[159]. - The company has established a supervisory board consisting of 3 members, including 1 employee representative, complying with relevant laws and regulations[160]. - The company emphasizes transparency and investor relations, having issued over 100 reports, including resolutions and regular reports, in 2024[160]. - The company has committed to enhancing its information disclosure management system in accordance with regulatory requirements[187]. Employee Management - The total number of employees at the end of the reporting period is 4,098, with 68 in the parent company and 4,030 in major subsidiaries[193]. - The company employs 1,564 production personnel, 935 sales personnel, 832 technical personnel, 157 financial personnel, and 610 administrative personnel[193]. - The educational background of employees includes 29 with a doctorate, 241 with a master's degree, 1,379 with a bachelor's degree, 1,152 with an associate degree, and 1,297 with a technical secondary school education or below[193]. - The company has optimized its compensation plan for high-performing employees, providing competitive salary policies to maintain industry leadership[194]. - Annual training programs are implemented based on the principle of "differentiation by person and position," covering various employee categories[195]. Strategic Initiatives - The company plans to expand its market presence through strategic partnerships and acquisitions in the next fiscal year[171]. - The company aims to achieve a market expansion strategy that targets a 20% increase in market share by 2025[171]. - The company plans to establish a new international innovation center in Shanghai, set to commence operations in the second half of 2025[137]. - The company is focused on expanding its market presence and enhancing its product pipeline through strategic R&D initiatives[174].

亿帆医药股份有限公司 关于控股子公司再次通过高新技术企业认定的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-017 二、对公司的影响 2025年4月23日 本次认定系上海亿一原《高新技术企业证书》有效期满后进行的重新认定。 根据《中华人民共和国企业所得税法》《高新技术企业认定管理办法》等相关规 定，上海亿一可连续三年（2024 年—2026 年）享受国家关于高新技术企业所得 税的优惠政策，即按 15%的税率缴纳企业所得税。 亿帆医药股份有限公司（以下简称"公司"）控股子公司亿一生物医药开发 （上海）有限公司（以下简称"上海亿一"）于2025年4月22日收到由上海市科 学技术委员会、上海市财政局和国家税务总局上海市税务局联合颁发的《高新技 术企业证书》，具体如下： 一、证书相关情况 亿帆医药股份有限公司董事会 | 企业名称 | 证书编号 | 发证时间 | 有效期 | | --- | --- | --- | --- | | 亿一生物医药开发（上海）有限公司 | GR202431003754 | ...

Core Viewpoint - The company has received approval for its hydrobromide etizolam injection, marking its entry into the controlled substance market and indicating a successful transition from R&D to production and sales [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for hydrobromide etizolam injection from the National Medical Products Administration (NMPA) on April 8, 2025 [1]. - The drug was developed and produced independently by the subsidiary and is classified as a Class 3 chemical drug, which is equivalent to passing the consistency evaluation [1]. - Currently, only one other company in China has received approval for hydrobromide etizolam injection, while another is in the review stage for generic drug production [1]. Group 2: Market Potential - Hydrobromide etizolam injection is a central analgesic, particularly effective for cancer pain and postoperative pain, and works by binding to kappa-opioid receptors to inhibit pain transmission [2]. - The domestic market for analgesics, including anesthetic analgesics and pain relievers, had a sales scale of approximately 19 billion yuan in 2023, indicating significant growth potential [2]. - The approval of this drug represents the company's first entry into the controlled substance market, providing new growth momentum through new markets, fields, and products [2]. Group 3: Earnings Forecast - The company's earnings per share (EPS) are projected to be 0.33 yuan, 0.51 yuan, and 0.64 yuan for the years 2024, 2025, and 2026, respectively [3].

Core Viewpoint - Yifan Pharmaceutical has received the drug registration certificate for Hydrochloride Etizolam Injection, marking its entry into the controlled substance market and enhancing its product portfolio [1][4]. Group 1: Drug Registration Information - The drug name is Hydrochloride Etizolam Injection, classified as a chemical drug of category 3 [2][3]. - The approval conclusion states that the product meets the requirements for drug registration according to Chinese regulations [1][2]. - The drug registration certificate was issued on April 8, 2025, with a validity period until March 31, 2030 [3]. Group 2: Product Overview - Hydrochloride Etizolam Injection is indicated for pain relief, particularly for cancer pain and postoperative pain [2]. - The company submitted the drug application in June 2023, received acceptance in July 2023, and obtained the research approval for controlled substances in September 2023 [2]. - The product is the first of its kind in China to pass the consistency evaluation for generic drugs [2]. Group 3: Market and Financial Impact - The domestic sales of Hydrochloride Etizolam Injection reached 128 million yuan in 2023 [2]. - The company has invested approximately 10.02 million yuan in the research and development of this product [2]. - The approval of this product is expected to positively impact the company's performance and enhance its competitiveness in the pharmaceutical sector [4].

Core Viewpoint - Yifan Pharmaceutical (002019) has received approval for its drug, Hydrobromide Etizolam Injection, from the National Medical Products Administration, marking a significant milestone in its product development and market entry [1] Group 1: Product Approval and Market Entry - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for Hydrobromide Etizolam Injection on April 8, 2025 [1] - The drug is indicated for pain relief, particularly for cancer pain and postoperative pain [1] - Yifan Pharmaceutical submitted the drug marketing application in June 2023 and received acceptance in July 2023 [1] Group 2: Market Position and Financials - As of the report date, the company is the first in China to pass the consistency evaluation for generic drugs [1] - The domestic sales revenue for 2023 reached 128 million yuan [1] - The company invested approximately 10.02 million yuan in research and development [1]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, Tonghe Pharmaceutical, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a 1.20% increase, surpassing the CSI 300 index by 2.57 percentage points. Sub-sectors such as innovative drugs, new medical infrastructure, and pharmacies performed well, while pharmaceutical outsourcing, medical devices, and hospitals lagged behind [6][36]. - There is a significant unmet need for Obstructive Sleep Apnea (OSA) treatment, with GLP-1RA drugs showing remarkable efficacy. The FDA approved Tirzepatide as the first and only prescription drug for treating moderate to severe OSA in adults with obesity [5][26]. Summary by Sections Industry Perspective and Investment Recommendations - OSA is linked to various health issues, including hypertension, and has a high prevalence among adults in China, with 176 million affected. The prevalence of hypertension among OSA patients is notably high [16][17]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market. The upcoming AACR and ASCO meetings are expected to catalyze interest in biotech innovations [30][31]. Industry Performance - The pharmaceutical sector's performance is highlighted, with innovative drugs and medical infrastructure leading the gains. The overall industry P/E ratio stands at 26.88, with a premium of 30.38% compared to the broader A-share market [36]. Company Dynamics - Notable company updates include: - Fuyuan Pharmaceutical reported a revenue of 3.446 billion yuan for 2024, a 3.17% increase year-on-year [37]. - Jingxin Pharmaceutical announced a share buyback totaling approximately 350 million shares [37]. - Heng Rui Medicine received approval for a new indication for its innovative drug, indicating ongoing development and regulatory progress [37].

Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company has shown a recovery in performance and is actively expanding into new business areas [1] - The vitamin product segment is expected to recover, while the pharmaceutical segment remains under pressure [9] - The company is implementing a "vertical and horizontal" strategy to expand its business and new product offerings [9] Financial Performance Summary - The company's revenue for 2023 was 1,095 million, with a projected increase to 1,243 million in 2024, representing a year-on-year growth of 13.6% [5] - Operating profit is expected to rise from 207 million in 2023 to 355 million in 2024, reflecting a significant growth of 71.6% [5] - Net profit attributable to the parent company is forecasted to increase from 192 million in 2023 to 309 million in 2024, a growth of 60.8% [5] - Earnings per share are projected to grow from 0.35 in 2023 to 0.57 in 2024 [5] - The gross margin is expected to be 58.4% in 2024, with a net margin of 24.9% [5] Earnings Forecast and Investment Recommendations - The report adjusts revenue forecasts for vitamin products and pharmaceuticals while increasing the gross margin for vitamin products [3] - The projected earnings per share for 2025-2027 are 0.88, 1.05, and 1.36 respectively [3] - Based on comparable companies, a target price of 14.96 is set for 2025, corresponding to a 17 times price-to-earnings ratio [3]

Group 1 - The government work report sets a GDP growth target of around 5% for 2025, with a fiscal deficit rate of 4% and a CPI target of 2%, aligning with market expectations [9][36] - The report emphasizes the importance of expanding domestic demand and boosting consumption as key drivers for economic growth, reflecting a strong commitment to stimulate the consumer market [27][28] - The focus on new technologies and emerging industries, particularly in artificial intelligence and digital economy, is highlighted as a priority for future development, indicating a significant investment opportunity in the tech sector [2][6] Group 2 - The report outlines ten measures to boost consumption, including enhancing service consumption and improving the quality of consumer goods, which is expected to benefit companies in the consumer sector [27][28] - The emphasis on high-quality development and the need to combat "involution" in the transportation industry suggests a shift towards more sustainable and efficient practices, which could impact logistics and transport companies positively [21][23] - The report mentions the importance of the low-altitude economy and new emerging industries, indicating potential growth areas for companies involved in logistics technology and smart transportation solutions [24][25] Group 3 - The government plans to issue 1.3 trillion yuan in special bonds to support consumption upgrades, which is expected to significantly stimulate demand in sectors like home improvement and consumer electronics [32][34] - The report indicates a strong focus on the integration of advanced manufacturing and modern service industries, suggesting opportunities for companies that can adapt to this evolving landscape [10][22] - The commitment to maintaining a stable monetary policy environment, with potential for interest rate cuts, is likely to create favorable conditions for investment in various sectors, particularly real estate and consumer goods [37][39]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].